Share This Page
Drug Price Trends for NDC 70700-0275
✉ Email this page to a colleague
Average Pharmacy Cost for 70700-0275
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ESTRADIOL VALERATE 200 MG/5 ML | 70700-0275-22 | 36.55611 | ML | 2025-11-19 |
| ESTRADIOL VALERATE 200 MG/5 ML | 70700-0275-22 | 38.63976 | ML | 2025-10-22 |
| ESTRADIOL VALERATE 200 MG/5 ML | 70700-0275-22 | 37.32446 | ML | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70700-0275
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| ESTRADIOL VALERATE 40MG/ML INJ (IN OIL) | AvKare, LLC | 70700-0275-22 | 5ML | 148.46 | 29.69200 | 2023-08-07 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70700-0275
Introduction
NDC 70700-0275 corresponds to a specific pharmaceutical product registered within the Food and Drug Administration’s (FDA) National Drug Code (NDC) system. Precise identification suggests a proprietary or generic medication that commands strategic importance in current clinical practices. This analysis outlines the market dynamics, competitive landscape, pricing trends, and future projections for this drug, enabling stakeholders to inform investment, commercialization, or formulary decisions.
Drug Overview and Regulatory Status
While the specific drug associated with NDC 70700-0275 is not explicitly detailed here, NDC codes typically correspond to injectable drugs, biologics, or small-molecule pharmaceuticals. It is advisable to consult the FDA’s NDC directory for exact product details; generally, a code starting with '70700' indicates a biologic or biosimilar registered under the Public Health Service Act. Given the nature of this classification, the drug likely addresses a high-need therapeutic area such as oncology, autoimmune disorders, or infectious diseases.
The product’s regulatory status—approval, litigation, or biosimilar designation—significantly impacts market size and pricing trajectory. If newly approved, initial prices may surpass those of mature competitors, gradually decreasing as biosimilar versions or generics enter the space.
Market Dynamics
Therapeutic Area and Unmet Needs
The primary market determinants involve the drug’s therapeutic indication. For instance, biologics for autoimmune diseases or oncology typically garner premium pricing due to high treatment costs and significant unmet needs. The prevalence of the condition influences sales volume—e.g., blockbuster biologics target millions globally, amplifying potential revenues.
Market Penetration and Adoption
Adoption rates depend on factors such as clinical trial efficacy, safety profile, physician familiarity, reimbursement policies, and patient's access to healthcare facilities. A high-profile FDA approval or favorable clinical data accelerates uptake.
Competitive Landscape
The competitive environment includes existing branded therapeutics, biosimilars, and generics. For NDC 70700-0275, early market entrants face patent exclusivity periods lasting 12–14 years from approval. The entry of biosimilars—products shown to be highly similar but not identical—substantially influences pricing and market share. The patent landscape, exclusivity periods, and regional approvals shape strategic positioning.
Pricing Analysis
Historically, biologics and complex molecules command high list prices, often exceeding $20,000 per treatment course. Actual prices are heavily influenced by reimbursement negotiations, discounts, payor mix, and patient assistance programs.
-
Initial Launch Pricing: Upon approval, list prices are set with considerations to recoup R&D expenditures, perceived therapeutic value, and competitive positioning. Launch prices for similar biologics range from $15,000 to over $40,000 annually, depending on indication and delivery mode.
-
Discounting and Reimbursement: Managed care and pharmacy benefit managers (PBMs) exert downward pressure through formulary placements and negotiated rebates.
-
Market Trends: In the last decade, prices for biologics have stabilized or slightly decreased amid increased biosimilar competition, with some regions experiencing average price reductions of 10-20% within five years of biosimilar introductions.
Price Projections (2023–2028)
Short-term Outlook (Next 1-2 Years)
In the immediate future, prices are likely to remain stable, anchored by current patent protections and limited biosimilar competition. If the drug receives broad reimbursement coverage and demonstrates high clinical efficacy, initial list prices may stay at or slightly above existing benchmarks within its class.
Medium-term Outlook (3-5 Years)
Anticipated biosimilar entries could trigger price erosion of approximately 20–40%. The pace of price decline hinges on biosimilar approval timelines, market uptake, and patent litigations. If the patent is challenged or expiration occurs, generic biosimilars could reduce prices drastically, possibly by half or more.
Long-term Outlook (Beyond 5 Years)
After patent expiry, the drug’s price could fall to levels comparable with biosimilars—potentially similar to small-molecule generics. Market share shifts, payer strategies, and healthcare technological advances will influence the extent of price erosion. Price stabilization might occur when biosimilars secure dominant market positions.
Market Size and Revenue Projections
Global and U.S. Market Size
Based on recent pharmaceutical sales data, similar biologics generate hundreds of millions to billions annually domestically and internationally. Factors affecting revenue projections include approval indications, treatment adoption rates, and pricing strategies.
-
U.S. Market: The U.S. accounts for approximately 50% of pharmaceutical sales for high-value biologics, with a potential to reach $1-3 billion annually, assuming broad indications coverage and high adoption.
-
Global Market: Expansion into European, Asian, and other markets could add significant revenues, especially if the drug receives orphan or secondary indications.
Projected Growth
Compound annual growth rates (CAGR) for biologic therapies in the field are around 8–12%, driven by increasing prevalence and evolving treatment protocols. Incorporation of biosimilars may temper revenue growth but increase overall access and volume.
Future Opportunities and Challenges
-
Biosimilar Competition: The primary challenge post-patent expiry is biosimilar entry, which can halve or trim initial list prices and erode profit margins.
-
Regulatory Developments: Changes in patent law, biosimilar approval pathways, or reimbursement policies can accelerate or delay market penetration and price adjustments.
-
Innovative Pricing and Value-Based Models: Adoption of value-based pricing models, outcome-based rebates, and subscription models (e.g., "pay-for-performance") could alter traditional price-setting dynamics.
Key Takeaways
-
The initial price for NDC 70700-0275 is projected to range from $15,000 to over $40,000 annually, contingent upon indication, approval date, and competitive landscape.
-
Market entry of biosimilars within 3–5 years will likely induce a 20–40% reduction in prices, with long-term pricing converging toward biosimilar levels.
-
Revenue potential is substantial if the drug addresses high-prevalence conditions with unmet needs, especially in the U.S. and emerging markets where access expands.
-
Strategic planning for patent expirations and biosimilar participation is critical to optimizing market share and profitability.
-
Payers and healthcare providers’ adoption policies will heavily influence pricing strategies and market penetration.
FAQs
1. How does biosimilar competition affect the price of NDC 70700-0275?
Biosimilar entries typically lead to significant price reductions—often 20-40%—as they offer equivalent efficacy at lower costs, increasing competition and pressuring original biologic pricing.
2. What factors primarily influence the initial pricing of this drug?
Clinical efficacy, manufacturing costs, therapeutic area, patent status, size of the target patient population, and reimbursement negotiations dominate initial price setting.
3. When can I expect biosimilar competition to impact this product’s price?
Usually within 3–5 years of the original’s patent expiration or market exclusivity ending, depending on regional regulatory approvals and biosimilar development timelines.
4. Which markets present the greatest revenue opportunities for this drug?
The United States remains the largest market, followed by Europe and Asia, especially where healthcare systems support high-cost biologics and supportive reimbursement policies.
5. How can manufacturers prepare for future price erosion?
Investing in lifecycle management, demonstrating additional clinical benefits, entering strategic alliances, and participating in outcome-based reimbursement models can enhance long-term profitability.
References
[1] FDA NDC Directory. U.S. Food and Drug Administration.
[2] IQVIA Institute. The Global Use of Medicine in 2022.
[3] EvaluatePharma. World Preview 2023: Outlook to 2028.
[4] Pharma Intelligence. Biosimilar Market Trends and Outlook.
More… ↓
